Baird Initiates Coverage on Amicus Therapeutics(NASDAQ:FOLD). The shares have been rated Neutral. The rating by Baird was issued on Apr 14, 2016.
In a different note, Goldman Sachs said it Initiates Coverage on Amicus Therapeutics, according to a research note issued on Mar 30, 2016. The shares have been rated ‘Neutral’ by the firm. On Mar 8, 2016, Janney Capital said it Upgrades its rating on Amicus Therapeutics. The shares have been rated ‘Buy’ by the firm. On Feb 23, 2016, JP Morgan said it Maintains its rating on Amicus Therapeutics. In the research note, the firm Lowers the price-target to $18.00 per share. The shares have been rated ‘Overweight’ by the firm.
Amicus Therapeutics (FOLD) made into the market gainers list on Mondays trading session with the shares advancing 1.94% or 0.15 points. Due to strong positive momentum, the stock ended at $7.9, which is also near the day’s high of $8.005. The stock began the session at $7.65 and the volume stood at 21,04,910 shares. The 52-week high of the shares is $18.83 and the 52 week low is $4.985. The company has a current market capitalization of $989 M and it has 12,52,11,393 shares in outstanding.
Amicus Therapeutics(FOLD) last announced its earnings results on Feb 26, 2016 for Fiscal Year 2015 and Q4.Earnings per share were $-0.35. Analysts had estimated an EPS of $-0.31.
Several Insider Transactions has been reported to the SEC. On Nov 10, 2015, Margaret G Mcglynn (director) purchased 10,000 shares at $10.27 per share price.Also, On Oct 5, 2015, Kenneth Peist (VP, Legal & IP) sold 10,000 shares at $13.14 per share price.On Oct 5, 2015, Daphne Quimi (Vice President Finance) sold 11,250 shares at $13.13 per share price, according to the Form-4 filing with the securities and exchange commission.
Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.